<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29468">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02723084</url>
  </required_header>
  <id_info>
    <org_study_id>M15-828</org_study_id>
    <nct_id>NCT02723084</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection</brief_title>
  <acronym>CERTAIN-2</acronym>
  <official_title>A Randomized, Open-Label, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of 8 weeks of treatment
      with the combination regimen ABT-493/ABT-530 in comparison to sofosbuvir plus ribavirin for
      12 weeks in Hepatitis C Virus Genotype 2 (GT2) infected participants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who achieve 12-week sustained virologic response (SVR12) (non-inferiority analysis)</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>Hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification. The primary outcome measure is the non-inferiority analysis of the SVR12 rate of the ABT-493/ABT-530 arm to that of the SOF/RBV arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants treated with ABT-493/ABT-530 who achieve 12-week sustained virologic response (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with on-treatment virologic failure</measure>
    <time_frame>Up to 12 weeks while on treatment</time_frame>
    <description>The percentage of subjects with confirmed greater than 1 log10 IU/mL increase in HCV RNA above nadir during treatment, or with confirmed HCV RNA greater than or equal to 100 IU/mL after achieving unquantifiable HCV RNA during treatment, or with quantifiable HCV RNA at the end of treatment with at least 6 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Post-Treatment relapse</measure>
    <time_frame>Up to 12 weeks after the last dose of study drug</time_frame>
    <description>Percentage of participants with confirmed quantifiable HCV RNA after completion of treatment among participants with unquantifiable HCV RNA at the end of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Hepatitis C Virus</condition>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530, GT2 without cirrhosis (8 wks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 in HCV GT2 infected participants without cirrhosis for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sofosbuvir plus ribavirin, GT2 without cirrhosis (12 wks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sofosbuvir plus ribavirin in HCV GT2 infected participants without cirrhosis for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493/ABT-530</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493/ABT-530, GT2 without cirrhosis (8 wks)</arm_group_label>
    <other_name>Glecaprevir/Pibrentasvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>sofosbuvir plus ribavirin, GT2 without cirrhosis (12 wks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Capsule</description>
    <arm_group_label>sofosbuvir plus ribavirin, GT2 without cirrhosis (12 wks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening central laboratory result indicating HCV GT-2 infection without
             co-infection of any other genotype.

          -  Subject has positive anti-HCV Ab and plasma HCV RNA viral load greater than or equal
             to 1000 IU/mL at Screening Visit.

          -  Chronic HCV infection defined as one of the following:

               -  Positive for anti-HCV antibody (Ab) and/or HCV RNA at least 6 months before
                  Screening; or

               -  A liver biopsy consistent with chronic HCV infection.

          -  Subject must be HCV Direct-acting antiviral agent (DAA) treatment-na√Øve (i.e.,
             patient has not received a single dose of any approved or investigational DAA). Prior
             HCV treatment using IFNs with or without ribavirin is acceptable. Previous HCV
             Interferon (IFN) based treatment must have been completed greater than or equal to 2
             months prior to screening.

        Exclusion Criteria:

          -  Recent (within 6 months prior to study drug administration) history of drug or
             alcohol abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          -  Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti
             human immunodeficiency virus antibody (HIV Ab).

          -  Requirement for and inability to safely discontinue contraindicated medications or
             supplements at least 2 weeks or 10 half-lives (whichever is longer) prior to the
             first dose of any study drug.

          -  Clinically significant abnormalities, other than HCV-infection, based upon the
             results of a medical history, physical examination, vital signs, laboratory profile,
             and a 12-lead electrocardiogram (ECG) that make the subject an unsuitable candidate
             for this study in the opinion of the investigator, including, but not limited to:

               -  Uncontrolled diabetes as defined by a glycated hemoglobin (hemoglobin A1C) level
                  &gt; 8.5% at the Screening Visit.

               -  Active or suspected malignancy or history of malignancy (other than basal cell
                  skin cancer or cervical carcinoma in situ) in the past 5 years, or any history
                  of HCC.

               -  Uncontrolled cardiac, respiratory, gastrointestinal, hematologic, neurologic,
                  psychiatric, or other medical disease or disorder, which is unrelated to the
                  existing HCV infection.

          -  Any cause of liver disease other than chronic HCV-infection, including but not
             limited to the following:

               -  Hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, autoimmune
                  hepatitis, alcoholic liver disease, or steatohepatitis considered to be the
                  primary cause of the liver disease rather than concomitant/incidental with HCV
                  infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koji Kato, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148636</name>
      <address>
        <city>Beppu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148511</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148631</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148536</name>
      <address>
        <city>Fukuoka-shi, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148549</name>
      <address>
        <city>Fukuoka-shi,Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148537</name>
      <address>
        <city>Gifu-shi, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148510</name>
      <address>
        <city>Gifu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148528</name>
      <address>
        <city>Gifu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148509</name>
      <address>
        <city>Hamamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148302</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148524</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148514</name>
      <address>
        <city>Ikeda-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148538</name>
      <address>
        <city>Inzai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148553</name>
      <address>
        <city>Iruma-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148299</name>
      <address>
        <city>Kagoshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148515</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148541</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148517</name>
      <address>
        <city>Kanazawa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148527</name>
      <address>
        <city>Kashihara-shi, Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148303</name>
      <address>
        <city>Kawasaki-shi, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148551</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148526</name>
      <address>
        <city>Kyoto-shi, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148508</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148633</name>
      <address>
        <city>Maebashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148521</name>
      <address>
        <city>Matsumoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148534</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148535</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148544</name>
      <address>
        <city>Meguro-ku , Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148507</name>
      <address>
        <city>Mie</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148531</name>
      <address>
        <city>Nagasaki-shi, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148539</name>
      <address>
        <city>Nagoya-shi, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148548</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148632</name>
      <address>
        <city>Nishinomiya-shi, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148516</name>
      <address>
        <city>Obihiro-shi, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148523</name>
      <address>
        <city>Ogaki-shi,Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148300</name>
      <address>
        <city>Okayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148543</name>
      <address>
        <city>Okayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148550</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148504</name>
      <address>
        <city>Osaka-shi, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148638</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148540</name>
      <address>
        <city>Osakasayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148505</name>
      <address>
        <city>Saga-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148513</name>
      <address>
        <city>Saitama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148547</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148545</name>
      <address>
        <city>Sapporo-shi, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148301</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148630</name>
      <address>
        <city>Shimotsuka-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148520</name>
      <address>
        <city>Suita-shi, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148518</name>
      <address>
        <city>Suita-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148503</name>
      <address>
        <city>Takamatsu-shi, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148925</name>
      <address>
        <city>Takasaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148530</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148552</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148634</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148533</name>
      <address>
        <city>Toyoake-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148506</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148542</name>
      <address>
        <city>Yamanashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148525</name>
      <address>
        <city>Yokohama-shi, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148529</name>
      <address>
        <city>Yokohama-shi, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148546</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148637</name>
      <address>
        <city>Yufu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>March 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Non-cirrhotic</keyword>
  <keyword>Hepatitis C Genotype 2</keyword>
  <keyword>Chronic Hepatitis C Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
